Search

Your search keyword '"Novartis Pharma AG -- Reports"' showing total 139 results
Start Over Descriptor "Novartis Pharma AG -- Reports" Topic pharmaceutical industry -- reports
139 results on '"Novartis Pharma AG -- Reports"'

1. Paroxysmal Nocturnal Hemoglobinuria Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers

Subjects
Novartis Pharma AG -- Reports, Regeneron Pharmaceuticals Inc. -- Reports, BioCryst Pharmaceuticals Inc. -- Reports, Reports, Eculizumab -- Reports, Business research -- Reports, Ravulizumab -- Reports, Pharmaceutical industry -- Reports, Business -- Research
Abstract

M2 PRESSWIRE-November 4, 2024-: Paroxysmal Nocturnal Hemoglobinuria Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers (C)1994-2024 M2 COMMUNICATIONS RDATE:01112024 DelveInsight's, 'Paroxysmal Nocturnal Haemoglobinuria Pipeline Insight 2024' report [...]

Published
2024

2. Refractory Multiple Myeloma Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers

Subjects
Novartis Pharma AG -- Reports, Business -- Research, Multiple myeloma -- Reports, Carfilzomib -- Reports, Pharmaceutical industry -- Reports, Business, Business, international
Abstract

M2 PRESSWIRE-October 28, 2024-: Refractory Multiple Myeloma Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers (C)1994-2024 M2 COMMUNICATIONS RDATE:28102024 DelveInsight's, 'Refractory Multiple Myeloma Pipeline Insight 2024' report [...]

Published
2024

3. Rheumatoid Arthritis Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers

Subjects
Novartis Pharma AG -- Reports, Bristol-Myers Squibb Co. -- Reports, Business -- Research, Rheumatoid factor -- Reports, B cells -- Reports, Arthritis -- Reports, Adalimumab -- Reports, Pharmaceutical industry -- Reports, Business, Business, international
Abstract

M2 PRESSWIRE-October 24, 2024-: Rheumatoid Arthritis Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers (C)1994-2024 M2 COMMUNICATIONS RDATE:23102024 DelveInsight's, 'Rheumatoid Arthritis Pipeline Insight 2024' report provides comprehensive [...]

Published
2024

4. Neuroendocrine Tumors Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers

Subjects
Novartis Pharma AG -- Reports, Reports, Business research -- Reports, Neuroendocrine tumors -- Reports, Copper Cu 64 dotatate -- Reports, Tumors -- Reports, Pembrolizumab -- Reports, Pharmaceutical industry -- Reports, Lanreotide -- Reports, Antineoplastic agents -- Reports, Business -- Research, Antimitotic agents -- Reports
Abstract

M2 PRESSWIRE-October 10, 2024-: Neuroendocrine Tumors Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers (C)1994-2024 M2 COMMUNICATIONS RDATE:09102024 DelveInsight's, 'Neuroendocrine tumors Pipeline Insight, 2024' report provides comprehensive [...]

Published
2024

5. FORM 8-K: Voyager Therapeutics, Inc. Files Current Report (Sep 05, 2024)

Subjects
United States. Securities and Exchange Commission -- Reports, Novartis Pharma AG -- Reports, Securities law -- Reports, Stock-exchange -- Reports, Pharmaceutical industry -- Reports, News, opinion and commentary, Securities Exchange Act
Abstract

Washington: Voyager Therapeutics, Inc., has filed FORM 8-K (Current Report) with the U.S. Securities and Exchange Commission on Sep 05, 2024: UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 [...]

Published
2024

6. Multiple Sclerosis Pipeline Drugs 2024 | TG Therapeutics, Immunic, Atara Biotherapeutics, ANOKION, ImStem Biotechnology, Merck Serono, CinnaGen, Immune Response BioPharma, Inc., Clene Nanomedicine, Ge

Subjects
Novartis Pharma AG -- Reports, Bristol-Myers Squibb Co. -- Reports, Biological products industry -- Reports, Business -- Research, Multiple sclerosis -- Drug therapy, Biotechnology -- Reports, Ofatumumab -- Reports, Drugs -- Reports, Pharmaceutical industry -- Reports, Business, Business, international
Abstract

M2 PRESSWIRE-August 12, 2024-: Multiple Sclerosis Pipeline Drugs 2024 | TG Therapeutics, Immunic, Atara Biotherapeutics, ANOKION, ImStem Biotechnology, Merck Serono, CinnaGen, Immune Response BioPharma, Inc., Clene Nanomedicine, Ge (C)1994-2024 M2 [...]

Published
2024

7. Food Allergy Market Size was USD 1,648 Million in 2023 and Expected to Grow by 2034, estimates DelveInsight

Subjects
Novartis Pharma AG -- Reports, Genentech Inc. -- Reports, Regeneron Pharmaceuticals Inc. -- Reports, Business -- Research, Omalizumab -- Reports, Biotechnology industry -- Reports, Brand equity -- Reports, Epidemiology -- Reports, Food allergy -- Reports, Pharmaceutical industry -- Reports, Business, Business, international
Abstract

M2 PRESSWIRE-June 26, 2024-: Food Allergy Market Size was USD 1,648 Million in 2023 and Expected to Grow by 2034, estimates DelveInsight (C)1994-2024 M2 COMMUNICATIONS RDATE:26062024 Food Allergy companies are [...]

Published
2024

8. FORM 8-K: ARVINAS, INC. Files Current Report (May 30, 2024)

Subjects
United States. Securities and Exchange Commission -- Reports, Novartis Pharma AG -- Reports, Securities law -- Reports, Stock-exchange -- Reports, Pharmaceutical industry -- Reports, News, opinion and commentary, Securities Exchange Act
Abstract

Washington: ARVINAS, INC., has filed FORM 8-K (Current Report) with the U.S. Securities and Exchange Commission on May 30, 2024: UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 __________________ [...]

Published
2024

9. Thyroid Cancer Pipeline Insights Report 2024

Subjects
Eisai Ltd. -- Reports, Novartis Pharma AG -- Reports, Business -- Research, Antineoplastic agents -- Reports, Thyroid cancer -- Reports, Pharmaceutical industry -- Reports, Antimitotic agents -- Reports, Business, Business, international
Abstract

M2 PRESSWIRE-February 28, 2024-: Thyroid Cancer Pipeline Insights Report 2024 (C)1994-2024 M2 COMMUNICATIONS RDATE:28022024 DelveInsight's, 'Thyroid Cancer Pipeline Insight 2024' report provides comprehensive insights about 40+ Thyroid Cancer companies and [...]

Published
2024

10. Non-Alcoholic Fatty Liver Disease Pipeline, FDA Approvals, Research and Developments, Future Perspectives, and Companies (Updated)

Subjects
Novartis Pharma AG -- Reports, Medical research -- Reports, Medicine, Experimental -- Reports, Business -- Research, Fatty liver -- Reports, Industrial research -- Switzerland, Pharmaceutical industry -- Reports, Research and development, Business, Business, international
Abstract

M2 PRESSWIRE-January 24, 2024-: Non-Alcoholic Fatty Liver Disease Pipeline, FDA Approvals, Research and Developments, Future Perspectives, and Companies (Updated) (C)1994-2024 M2 COMMUNICATIONS RDATE:23012024 DelveInsight's, 'Non-Alcoholic Fatty Liver Disease Pipeline Insight' [...]

Published
2024

11. Autoimmune Hepatitis Pipeline, Clinical Trials Studies, Emerging Drugs, Mergers and Acquisition, Licensing, Agreements & Collaborations, and Latest News 2023 (Updated)

Subjects
Novartis Pharma AG -- Reports, Pharmaceutical industry -- Reports, Acquisitions and mergers -- Reports, Business, Business, international
Abstract

M2 PRESSWIRE-November 9, 2023-: Autoimmune Hepatitis Pipeline, Clinical Trials Studies, Emerging Drugs, Mergers and Acquisition, Licensing, Agreements & Collaborations, and Latest News 2023 (Updated) (C)1994-2023 M2 COMMUNICATIONS RDATE:08112023 DelveInsight's, 'Autoimmune [...]

Published
2023

12. FORM 8-K: BeiGene, Ltd. Files Current Report (Sep 19, 2023)

Subjects
United States. Securities and Exchange Commission -- Reports, Novartis Pharma AG -- Reports, Securities law -- Reports, Stock-exchange -- Reports, Financial statements -- Reports, Securities industry -- Reports, Pharmaceutical industry -- Reports, Securities industry, News, opinion and commentary, Securities Exchange Act
Abstract

Washington: BeiGene, Ltd., has filed FORM 8-K (Current Report) with the U.S. Securities and Exchange Commission on Sep 19, 2023: UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________ [...]

Published
2023

13. Novartis Pharmaceuticals AG Reports Findings in Myelodysplastic Syndromes (Experiences and Support Needs of Caregivers of Patients with Higher-Risk Myelodysplastic Syndrome via Online Bulletin Board in the USA, Canada and UK)

Subjects
Novartis Pharma AG -- Reports, Medical research -- Reports, Medicine, Experimental -- Reports, Online information services -- Reports, Myelodysplastic syndromes -- Reports, Cancer patients -- Reports, Online services -- Reports, Information services -- Reports, Caregivers -- Reports, Pharmaceutical industry -- Reports, Online information service, Education, News, opinion and commentary
Abstract

2023 DEC 27 (VerticalNews) -- By a News Reporter-Staff News Editor at Education Letter -- New research on Hematologic Diseases and Conditions - Myelodysplastic Syndromes is the subject of a [...]

Published
2023

14. New Findings Reported from RTI Health Solutions Describe Advances in Asthma (Psychometric evaluation of an electronic Asthma Symptom Diary for young children)

Subjects
Novartis Pharma AG -- Reports, Asthma in children -- Reports, Medical research -- Reports, Medicine, Experimental -- Reports, Pediatrics -- Reports, Pharmaceutical industry -- Reports, Health
Abstract

2023 NOV 20 (NewsRx) -- By a News Reporter-Staff News Editor at Respiratory Therapeutics Week -- A new study on asthma is now available. According to news originating from the [...]

Published
2023

15. Research and Markets Adds Report: Food Allergy

Subjects
Genentech Inc. -- Reports, Novartis Pharma AG -- Reports, Regeneron Pharmaceuticals Inc. -- Reports, Omalizumab -- Reports, Biotechnology industry -- Reports, Food allergy -- Reports, Pharmaceutical industry -- Reports, Food and beverage industries
Abstract

Research and Markets has announced the addition of the Food Allergy - Pipeline Insight' report to its offerings. In a release, Research and Markets noted that report highlights include: The [...]

Published
2022

16. Vasculitis Pipeline 2023: Robust Pipeline With 20 + Key Pharma Companies Actively Working in the domain, observes DelveInsight | CytoDyn, ChemoCentryx, Roche, GlaxoSmithKline, Vifor Pharma

Subjects
Novartis Pharma AG -- Reports, Business -- Research, Vasculitis -- Reports, Monoclonal antibodies -- Reports, Pharmaceutical industry -- Reports, Business, Business, international
Abstract

M2 PRESSWIRE-March 21, 2023-: Vasculitis Pipeline 2023: Robust Pipeline With 20 + Key Pharma Companies Actively Working in the domain, observes DelveInsight | CytoDyn, ChemoCentryx, Roche, GlaxoSmithKline, Vifor Pharma (C)1994-2023 [...]

Published
2023

17. FORM 8-K: SomaLogic, Inc. Files Current Report (Jan 10, 2023)

Subjects
United States. Securities and Exchange Commission -- Reports, Novartis Pharma AG -- Reports, SomaLogic Inc. -- Reports, Securities law -- Reports, Biotechnology industry -- Reports, Stock-exchange -- Reports, Financial statements -- Reports, Pharmaceutical industry -- Reports, News, opinion and commentary, Securities Exchange Act
Abstract

Washington: SomaLogic, Inc., has filed FORM 8-K (Current Report) with Securities and Exchange Commission on Jan 10, 2023: UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT [...]

Published
2023

18. FORM 8-K: IONIS PHARMACEUTICALS, INC. Files Current Report (Jan 09, 2023)

Subjects
United States. Securities and Exchange Commission -- Reports, Novartis Pharma AG -- Reports, Ionis Pharmaceuticals, Inc. -- Reports, Stock-exchange -- Reports, Financial statements -- Reports, Pharmaceutical industry -- Reports, News, opinion and commentary, Securities Exchange Act
Abstract

Washington: IONIS PHARMACEUTICALS, INC., has filed FORM 8-K (Current Report) with Securities and Exchange Commission on Jan 09, 2023: UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K [...]

Published
2023

19. Propulsion of Nonalcoholic Steatohepatitis Pipeline as Novel and Extensive 150+ Therapies Likely to Enter in the Treatment Domain | DelveInsight

Subjects
Novartis Pharma AG -- Reports, Bristol-Myers Squibb Co. -- Reports, Gilead Sciences Inc. -- Reports, Pfizer Inc. -- Reports, Boehringer Ingelheim GmbH -- Reports, AstraZeneca PLC -- Reports, Biological products industry -- Reports, Business -- Research, Pharmaceutical industry -- Reports, General interest, News, opinion and commentary
Abstract

LAS VEGAS: DelveInsight Business Research LLP has issued the following news release: DelveInsight's 'Nonalcoholic Steatohepatitis Pipeline Insight - 2022' report provides comprehensive global coverage of available, marketed, and pipeline nonalcoholic [...]

Published
2022

20. New Heart Failure Study Findings Have Been Reported by Investigators at Georg-August-University (Serelaxin Alleviates Cardiac Fibrosis Through Inhibiting Endothelial-to-mesenchymal Transition Via Rxfp1)

Subjects
Novartis Pharma AG -- Reports, Heart failure -- Research -- Reports, Physical fitness -- Reports, Angiotensin II -- Research -- Reports, Endothelium -- Reports, Stem cells -- Reports, Pharmaceutical industry -- Reports, Fibrosis -- Research -- Reports, Hormones, Finance, Diseases, Obesity, Heart diseases, Cardiovascular diseases, Editors, Health
Abstract

2020 APR 11 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Investigators publish new report on Heart Disorders and Diseases - Heart Failure. [...]

Published
2020

21. FORM 8-K: Precision BioSciences, Inc. Files Current Report (Updated on JUL 18, 2022)

Subjects
United States. Securities and Exchange Commission -- Reports, Novartis Pharma AG -- Reports, Securities law -- Reports, Biotechnology industry -- Reports, Stock-exchange -- Reports, Financial statements -- Reports, Pharmaceutical industry -- Reports, News, opinion and commentary, Securities Exchange Act
Abstract

Washington: Precision BioSciences, Inc., has filed FORM 8-K (Current Report) with Securities and Exchange Commission on JUL 18, 2022: UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K [...]

Published
2022

22. FORM 8-K: Mallinckrodt plc Files Current Report (Updated on JUN 30, 2022)

Subjects
United States. Securities and Exchange Commission -- Reports, Novartis Pharma AG -- Reports, Stratatech Corp. -- Reports, Mallinckrodt PLC -- Reports, Biological products industry -- Reports, Securities law -- Reports, Financial statements -- Reports, Pharmaceutical industry -- Reports, News, opinion and commentary, Securities Exchange Act
Abstract

Washington: Mallinckrodt plc, has filed FORM 8-K (Current Report) with Securities and Exchange Commission on JUN 30, 2022: UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT [...]

Published
2022

23. FORM 8-K: Precision BioSciences, Inc. Files Current Report (Updated on JUN 21, 2022)

Subjects
United States. Securities and Exchange Commission -- Reports, Novartis Pharma AG -- Reports, Employers -- Reports, Securities law -- Reports, Biotechnology industry -- Reports, Pharmaceutical industry -- Reports, News, opinion and commentary, Securities Exchange Act
Abstract

Washington: Precision BioSciences, Inc., has filed FORM 8-K (Current Report) with Securities and Exchange Commission on JUN 21, 2022: UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K [...]

Published
2022

24. The Worldwide Neutropenia Industry is Projected to Reach $5.4 Billion by 2027

Subjects
Novartis Pharma AG -- Reports, Supply and demand -- Reports, Neutropenia -- Reports, Pharmaceutical industry -- Reports, Banking, finance and accounting industries
Abstract

(GlobeNewswire) - The 'Global Neutropenia Market (2022-2027) by Treatment, Distribution Channel, Geography, Competitive Analysis, and the Impact of Covid-19 with Ansoff Analysis' report has been added to ResearchAndMarkets.com's offering. The [...]

Published
2022

26. Researchers from Royal Sussex County Hospital Detail Findings in Tuberous Sclerosis (Renal angiomyolipoma in patients with tuberous sclerosis complex: findings from the TuberOus SClerosis registry to increase disease Awareness)

Subjects
Novartis Pharma AG -- Reports, Women's health -- Reports, Medical research -- Reports, Pharmaceutical industry -- Reports, Tuberous sclerosis -- Complications and side effects -- Research -- Care and treatment -- Reports, Genetic research, Health, Women's issues/gender studies
Abstract

2020 JAN 16 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- A new study on Genetic Diseases and Conditions - Tuberous Sclerosis is now available. [...]

Published
2020

27. Studies in the Area of Heart Failure Reported from University of Southern California [Patient Commitment to Health (PACT-Health) in the Heart Failure Population: A Focus Group Study of an Active Communication Framework for Patient-Centered ...]

Subjects
Novartis Pharma AG -- Reports, Heart failure -- Development and progression -- Reports, Physical fitness -- Reports, Medical research -- Reports, Pharmaceutical industry -- Reports, Obesity, Editors, Health, University of Southern California -- Reports
Abstract

2019 SEP 28 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Research findings on Heart Disorders and Diseases - Heart Failure are discussed [...]

Published
2019

28. Study Results from Novartis in the Area of Chemistry Reported (Derivation of Rapamycin: Adventures in Natural Product Chemistry)

Subjects
Novartis Pharma AG -- Reports, Antifungal agents -- Reports, Rapamycin -- Reports, Physical fitness -- Reports, Pharmaceutical industry -- Reports, Health
Abstract

2019 SEP 21 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Investigators publish new report on Chemistry. According to news reporting from Basel, [...]

Published
2019

29. Researchers at Kumamoto University Report New Data on Cancer (A Retrospective Study of Arterial Stiffness and Subsequent Clinical Outcomes In Cancer Patients Undergoing Percutaneous Coronary Intervention)

Subjects
Novartis Pharma AG -- Reports, Bayer Yakuhin Ltd. -- Reports, Daiichi Sankyo Company Ltd. -- Reports, Balloon angioplasty -- Reports, Physical fitness -- Reports, Cancer research -- Reports, Cardiology -- Reports, Cardiac patients -- Care and treatment -- Patient outcomes -- Reports, Pharmaceutical industry -- Reports, Cancer patients -- Care and treatment -- Patient outcomes -- Reports, Cardiovascular diseases -- Care and treatment -- Research -- Patient outcomes -- Reports, Stenosis, Medical research, Arterial stenosis, Obesity, Home care, Editors, Health
Abstract

2019 JUN 8 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Fresh data on Cancer are presented in a new report. According to [...]

Published
2019

30. Recent Findings in Vasculitis Described by Researchers from University of Liverpool (Vasculitis In Juvenile-onset Systemic Lupus Erythematosus)

Subjects
Novartis Pharma AG -- Reports, Lupus -- Research -- Reports, Systemic lupus erythematosus -- Research -- Reports, Vasculitis -- Research -- Reports, Physical fitness -- Reports, Medical research -- Reports, Pharmaceutical industry -- Reports, Obesity, Charities, Cardiovascular diseases, Lupus erythematosus, Charitable foundations, Editors, Health, University of Liverpool -- Reports
Abstract

2019 JUN 8 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- A new study on Cardiovascular Diseases and Conditions - Vasculitis is now [...]

Published
2019

31. Findings from ICON plc Provides New Data about Information Technology (Identification and mapping of worldwide sources of generic real-world data)

Subjects
Icon PLC -- Reports, Novartis Pharma AG -- Reports, Physical fitness -- Reports, Pharmaceutical industry -- Reports, Obesity, Technology, Generic drugs, Clinical trials, Medical research, Editors, Health
Abstract

2019 MAY 25 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- New research on Information Technology is the subject of a report. According [...]

Published
2019

32. Novartis phase III EXPAND study shows treatment with Mayzent has clinically meaningful positive impact on CPS in patients with SPMS

Subjects
Novartis Pharma AG -- Reports, Pharmaceutical industry -- Reports, Pharmaceuticals and cosmetics industries, Mayzent (Medication) -- Reports
Abstract

Novartis announced a new analysis of the phase III EXPAND study, demonstrating that treatment with Mayzent (siponimod) had a clinically meaningful positive impact on cognitive processing speed (CPS) in patients [...]

Published
2019

33. Recent Findings from F. Boyle and Co-Researchers Yields New Information on Breast Cancer (Hormone Receptor Positive, Her2 Negative Metastatic Breast Cancer: Impact of Cdk4/6 Inhibitors On the Current Treatment Paradigm)

Subjects
Novartis Pharma AG -- Reports, Pharmaceutical industry -- Reports, Breast cancer -- Drug therapy -- Reports, Cancer research -- Reports, Biochemistry -- Reports, Cancer metastasis -- Drug therapy -- Reports, Hormones -- Reports, Women's health -- Reports, Women, Epidermal growth factors, Editors, Health, Women's issues/gender studies
Abstract

2019 MAR 28 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- Research findings on Oncology - Breast Cancer are discussed in a new report. According [...]

Published
2019

34. Studies from Novartis Pharmaceuticals AG Add New Findings in the Area of Artificial Intelligence (Educational and Emotional Needs of Patients With Myelodysplastic Syndromes: an Ai Analysis of Multi-country Social Media)

Subjects
Novartis Pharma AG -- Reports, Medical research -- Reports, Medicine, Experimental -- Reports, Myelodysplastic syndromes -- Care and treatment, Artificial intelligence -- Reports, Natural language interfaces -- Reports, Social media -- Reports, Computational linguistics -- Reports, Language processing -- Reports, Pharmaceutical industry -- Reports, Artificial intelligence, Business, Pharmaceuticals and cosmetics industries, Health
Abstract

2022 OCT 24 (NewsRx) -- By a News Reporter-Staff News Editor at Pharma Business Week -- Research findings on Artificial Intelligence are discussed in a new report. According to news [...]

Published
2022

35. FORM 8-K: BEIGENE, LTD. Files Current Report (Updated on DEC 20, 2021)

Subjects
Novartis Pharma AG -- Reports, Securities law -- Reports, Antineoplastic agents -- Reports, Stock-exchange -- Reports, Financial statements -- Reports, Securities industry -- Reports, Pharmaceutical industry -- Reports, Antimitotic agents -- Reports, Securities industry, General interest, News, opinion and commentary, Securities Exchange Act
Abstract

Washington: BEIGENE, LTD., has filed FORM 8-K (Current Report) with Securities and Exchange Commission on DEC 20, 2021: UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________ Form 8-K [...]

Published
2021

36. Propulsion of Malignant Mesothelioma Pipeline as Novel and Extensive Therapies Enter the Treatment Domain, Anticipates DelveInsight

Subjects
Merck KGaA -- Reports, Novartis Pharma AG -- Reports, Pfizer Inc. -- Reports, Bristol-Myers Squibb Co. -- Reports, AstraZeneca PLC -- Reports, Mesothelioma -- Care and treatment, Pharmaceutical industry -- Reports, Banking, finance and accounting industries, Business
Abstract

Las Vegas, USA, Oct 13, 2021 (GLOBE NEWSWIRE via COMTEX) -- Propulsion of Malignant Mesothelioma Pipeline as Novel and Extensive Therapies Enter the Treatment Domain, Anticipates DelveInsight Malignant Mesothelioma is [...]

Published
2021

37. FORM 8-K: SOMALOGIC, INC. Files Current Report (Updated on SEP 08, 2021)

Subjects
United States. Securities and Exchange Commission -- Reports, Ernst & Young L.L.P. -- Reports, Novartis Pharma AG -- Reports, SomaLogic Inc. -- Reports, The NASDAQ Stock Market L.L.C. -- Reports, Employers -- Reports, Securities law -- Reports, Biotechnology industry -- Reports, Stock-exchange -- Reports, Accounting firms -- Reports, Securities industry -- Reports, Pharmaceutical industry -- Reports, Securities industry, General interest, News, opinion and commentary
Abstract

Washington: SOMALOGIC, INC., has filed FORM 8-K (Current Report) with Securities and Exchange Commission on SEP 08, 2021: UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT [...]

Published
2021

38. New Antifungals Study Results from Novartis Described (CYP3A but not P-gp plays a relevant role in the in vivo intestinal and hepatic clearance of the delta-specific phosphoinositide-3 kinase inhibitor leniolisib)

Subjects
Novartis Pharma AG -- Reports, Itraconazole -- Research -- Reports, Physical fitness -- Reports, Cytochrome P-450 -- Reports, Pharmaceutical industry -- Reports, Health
Abstract

2018 OCT 27 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Research findings on Drugs and Therapies - Antifungals are discussed in a [...]

Published
2018

39. Study shows Novartis' Ultibro Breezhaler improved cardiac function in COPD patients with lung hyperinflation

Subjects
Novartis Pharma AG -- Reports, Chronic obstructive lung disease -- Research -- Reports, Respiratory system agents -- Research -- Reports, Cardiac patients -- Reports, Heart -- Reports, Pharmaceutical industry -- Reports, Pharmaceuticals and cosmetics industries
Abstract

Novartis has announced the publication of the CLAIM study in the Lancet Respiratory Medicine, which demonstrated that treatment once-daily Ultibro Breezhaler (indacaterol/glycopyrronium 110/50 mcg) significantly improved lung and cardiac function, [...]

Published
2018

40. Novartis says psoriasis drug study shows improved quality of life over 5 years

Subjects
Novartis Pharma AG -- Reports, Dermatologic agents -- Research -- Reports, Psoriasis -- Research -- Drug therapy -- Reports, Pharmaceutical industry -- Reports, Business, News, opinion and commentary, Cosentyx (Medication) -- Reports
Abstract

Novartis announced additional results from the SCULPTURE study showing that two thirds of moderate to severe plaque psoriasis patients treated with Cosentyx reported no impact of skin disease on their [...]

Published
2018

41. New Findings in Cell Therapy Described from Novartis Pharmaceuticals K.K. (The Past, Present, and Future of Clinically Applied Chimeric Antigen Receptor-T-Cell Therapy)

Subjects
Novartis Pharma AG -- Reports, T cells -- Reports, Antigens -- Reports, Pharmaceutical industry -- Reports, Biotechnology industry, Business
Abstract

2022 MAR 14 (NewsRx) -- By a News Reporter-Staff News Editor at Proteomics Weekly -- Fresh data on cell therapy are presented in a new report. According to news reporting [...]

Published
2022

42. CAR T-Cell Therapy for Multiple Myeloma Market Pipeline Report 2021

Subjects
Novartis Pharma AG -- Reports, T cells -- Reports, Multiple myeloma -- Reports, Pharmaceutical industry -- Reports, General interest, News, opinion and commentary
Abstract

DUBLIN: Research and Markets has issued the following news release: The 'CAR T-Cell Therapy for Multiple Myeloma - Pipeline Insight, 2021' drug pipelines has been added to ResearchAndMarkets.com's offering. This [...]

Published
2021

43. CAR T-Cell Therapy for Multiple Myeloma Market Pipeline Report 2021 - ResearchAndMarkets.com

Subjects
Novartis Pharma AG -- Reports, T cells -- Reports, Multiple myeloma -- Reports, Pharmaceutical industry -- Reports, Business, Business, international
Abstract

DUBLIN -- The 'CAR T-Cell Therapy for Multiple Myeloma - Pipeline Insight, 2021' drug pipelines has been added to ResearchAndMarkets.com's offering. This 'CAR T-Cell Therapy for Multiple Myeloma - Pipeline [...]

Published
2021

44. CAR T-Cell Therapy for Multiple Myeloma Market Pipeline Report 2021

Subjects
Novartis Pharma AG -- Reports, T cells -- Reports, Multiple myeloma -- Reports, Pharmaceutical industry -- Reports, Business, Business, international
Abstract

M2 PRESSWIRE-June 9, 2021-: CAR T-Cell Therapy for Multiple Myeloma Market Pipeline Report 2021 (C)1994-2021 M2 COMMUNICATIONS RDATE:09062021 The 'CAR T-Cell Therapy for Multiple Myeloma - Pipeline Insight, 2021' drug [...]

Published
2021

45. Nasopharyngeal Cancer Pipeline Insight Report 2021: Comprehensive Insights for Approx 30 Companies and Pipeline Drugs

Subjects
Novartis Pharma AG -- Reports, Nasopharyngeal cancer -- Reports, Drugs -- Reports, Cancer -- Reports, Pharmaceutical industry -- Reports, Business, Business, international
Abstract

M2 PRESSWIRE-May 13, 2021-: Nasopharyngeal Cancer Pipeline Insight Report 2021: Comprehensive Insights for Approx 30 Companies and Pipeline Drugs (C)1994-2021 M2 COMMUNICATIONS RDATE:13052021 The 'Nasopharyngeal Cancer - Pipeline Insight, 2021' [...]

Published
2021

46. Nasopharyngeal Cancer Pipeline Insight Report 2021: Comprehensive Insights for Approx 30 Companies and Pipeline Drugs - ResearchAndMarkets.com

Subjects
Novartis Pharma AG -- Reports, Nasopharyngeal cancer -- Reports, Drugs -- Reports, Cancer -- Reports, Pharmaceutical industry -- Reports, Business, Business, international
Abstract

DUBLIN -- The 'Nasopharyngeal Cancer - Pipeline Insight, 2021' drug pipelines has been added to ResearchAndMarkets.com's offering. This 'Nasopharyngeal Cancer - Pipeline Insight, 2021,' report provides comprehensive insights about 30+ [...]

Published
2021

47. WHO Expert Committee on Specifications for Pharmaceutical Preparations

Subjects
United States. Food and Drug Administration -- Reports, Scientific Services -- Reports, Novartis Pharma AG -- Reports, Pfizer Inc. -- Reports, GlaxoSmithKline Biologicals S.A. -- Reports, Biological products industry -- Reports, Vaccines -- Reports, Pharmaceutical industry -- Reports, Health, Social sciences, International Atomic Energy Agency -- Reports, United Nations. Development Programme -- Reports
Abstract

9. Prequalification of priority essential medicines 9.1 Update on the Prequalification Programme managed by WHO 9.1.1 Progress report The Expert Committee was informed that, during restructuring, the three WHO Prequalification [...]

Published
2014

48. FORM 8-K: BEIGENE, LTD. Files Current Report (Updated on FEB 26, 2021)

Subjects
United States. Securities and Exchange Commission -- Reports, Novartis Pharma AG -- Reports, Securities law -- Reports, Stock-exchange -- Reports, Financial statements -- Reports, Securities industry -- Reports, Pharmaceutical industry -- Reports, Securities industry, General interest, News, opinion and commentary, Securities Exchange Act
Abstract

Washington: BEIGENE, LTD., has filed FORM 8K (Current Report) with Securities and Exchange Commission on FEB 26, 2021: UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________ Form 8-K [...]

Published
2021

49. Global Treatment Resistant Depression Pipeline Insight Report 2020

Subjects
Novartis Pharma AG -- Reports, Depression (Mood disorder) -- Drug therapy, Pharmaceutical industry -- Reports, General interest, News, opinion and commentary
Abstract

DUBLIN: Research and Markets has issued the following press release: The 'Treatment Resistant Depression - Pipeline Insight, 2020' drug pipelines has been added to ResearchAndMarkets.com's offering. This 'Treatment Resistant Depression [...]

Published
2020

50. Global Treatment Resistant Depression Pipeline Insight Report 2020 - ResearchAndMarkets.com

Subjects
Novartis Pharma AG -- Reports, Depression (Mood disorder) -- Drug therapy, Pharmaceutical industry -- Reports, Business, Business, international
Abstract

DUBLIN -- The 'Treatment Resistant Depression - Pipeline Insight, 2020' drug pipelines has been added to ResearchAndMarkets.com's offering. This 'Treatment Resistant Depression - Pipeline Insight, 2020,' report provides comprehensive insights [...]

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results